Arnold B. Gelb

5.8k total citations · 3 hit papers
59 papers, 4.2k citations indexed

About

Arnold B. Gelb is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Arnold B. Gelb has authored 59 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Molecular Biology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Arnold B. Gelb's work include Lymphoma Diagnosis and Treatment (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Renal cell carcinoma treatment (8 papers). Arnold B. Gelb is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Renal cell carcinoma treatment (8 papers). Arnold B. Gelb collaborates with scholars based in United States, South Korea and France. Arnold B. Gelb's co-authors include Roger A. Warnke, L. Jeffrey Medeiros, Norman Orentreich∥, Gary Friedman, Egil Jellum, Svein Hansen, Julie Parsonnet, Joseph H. Vogelman∥, Lawrence M. Weiss and Roger A. Warnke and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Arnold B. Gelb

57 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Helicobacter pylori Infection and Gastric Lymphoma

1994 1.5k citations Julie Parsonnet, Svein Hansen et al. New England Journal of Medicine profile →
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Andrea B. Apolo, Jeffrey R. Infante et al. profile →
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations Manish R. Patel, John Ellerton et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arnold B. Gelb United States	27	2.1k	1.4k	1.3k	975	796	59	4.2k
Carlos E. Bacchi Brazil	37	1.0k 0.5×	1.4k 1.0×	2.2k 1.6×	932 1.0×	418 0.5×	236	5.7k
Nadine Ectors Belgium	34	2.6k 1.2×	1.7k 1.2×	1.2k 0.9×	624 0.6×	446 0.6×	157	5.0k
Sung Pil Hong South Korea	36	1.3k 0.6×	1.1k 0.8×	1.8k 1.3×	991 1.0×	250 0.3×	170	4.1k
K Takenaka Japan	33	1.4k 0.6×	549 0.4×	1.2k 0.9×	599 0.6×	478 0.6×	135	3.9k
AC Wotherspoon United Kingdom	22	2.5k 1.2×	1.5k 1.0×	1.0k 0.8×	299 0.3×	1.1k 1.4×	35	4.8k
Ryoji Kushima Japan	45	2.7k 1.3×	3.0k 2.1×	2.0k 1.5×	1.5k 1.5×	659 0.8×	321	7.1k
Yoshiaki Nakamura Japan	29	782 0.4×	1.2k 0.9×	2.6k 2.0×	638 0.7×	1.9k 2.4×	233	5.0k
Jérôme Fayette France	33	979 0.5×	2.3k 1.6×	2.9k 2.2×	740 0.8×	1.1k 1.4×	201	5.1k
Donna J. Lager United States	39	1.3k 0.6×	1.3k 0.9×	780 0.6×	1.5k 1.5×	481 0.6×	87	4.9k
Stefan Biesterfeld Germany	37	764 0.4×	864 0.6×	1.2k 0.9×	1.1k 1.1×	448 0.6×	147	4.0k

Countries citing papers authored by Arnold B. Gelb

Since Specialization

Citations

This map shows the geographic impact of Arnold B. Gelb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnold B. Gelb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnold B. Gelb more than expected).

Fields of papers citing papers by Arnold B. Gelb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnold B. Gelb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnold B. Gelb. The network helps show where Arnold B. Gelb may publish in the future.

Co-authorship network of co-authors of Arnold B. Gelb

This figure shows the co-authorship network connecting the top 25 collaborators of Arnold B. Gelb. A scholar is included among the top collaborators of Arnold B. Gelb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnold B. Gelb. Arnold B. Gelb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gopal, Ajay K., Philippe Armand, Sattva S. Neelapu, et al.. (2025). Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022. Blood Advances. 9(13). 3383–3394. 1 indexed citations

Patel, Manish R., John Ellerton, Jeffrey R. Infante, et al.. (2017). Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. The Lancet Oncology. 19(1). 51–64. 429 indexed citations breakdown →

Apolo, Andrea B., John Ellerton, Jeffrey R. Infante, et al.. (2017). Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients. Annals of Oncology. 28. v300–v301. 17 indexed citations

Menezes, Daniel E. Lopes de, Kimberly Denis-Mize, Helen Ye, et al.. (2006). Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma. Journal of Immunotherapy. 30(1). 64–74. 22 indexed citations

Gelb, Arnold B., et al.. (1997). Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer. 80(9). 1768–1775. 77 indexed citations

Gelb, Arnold B., L. Jeffrey Medeiros, Yuan Yuan Chen, Lawrence M. Weiss, & Noel Weidner. (1997). Hodgkin’s Disease of the Esophagus. American Journal of Clinical Pathology. 108(5). 593–598. 16 indexed citations

Gelb, Arnold B. & Andrew D. Leavitt. (1997). Crossmatch‐compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion. 37(6). 624–630. 43 indexed citations

Srigley, John R., R. V. P. Hutter, Arnold B. Gelb, et al.. (1997). Current prognostic factors-renal cell carcinoma. Cancer. 80(5). 994–996. 90 indexed citations

Johnston, James O., Lynne S. Steinbach, & Arnold B. Gelb. (1997). Soft Tissue Mass in the Foot of a 39-Year-Old Woman. Clinical Orthopaedics and Related Research. 338(338). 271–274, 288. 1 indexed citations

10.

Johnston, James O., Lynne S. Steinbach, & Arnold B. Gelb. (1997). Painful Mass Adjacent to the Tibial Tubercle of a 14-Year-Old Boy. Clinical Orthopaedics and Related Research. 339(339). 282–284,288. 2 indexed citations

11.

Gelb, Arnold B., Martha L. Simmons, & Noel Weidner. (1996). Solitary Fibrous Tumor Involving the Renal Capsule. The American Journal of Surgical Pathology. 20(10). 1288–1295. 91 indexed citations

12.

Gelb, Arnold B., Robert V. Rouse, Ronald F. Dorfman, & Roger A. Warnke. (1994). Detection of Immunophenotypic Abnormalities in Paraffin-embedded B-lineage Non-Hodgkin’s Lymphomas. American Journal of Clinical Pathology. 102(6). 825–834. 39 indexed citations

13.

Parsonnet, Julie, Svein Hansen, Arnold B. Gelb, et al.. (1994). Helicobacter pylori Infection and Gastric Lymphoma. New England Journal of Medicine. 330(18). 1267–1271. 1491 indexed citations breakdown →

14.

Gelb, Arnold B., et al.. (1993). Infantile histiocytoid cardiomyopathy— Myocardial or conduction system hamartoma: What is the cell type involved?. Human Pathology. 24(11). 1226–1231. 28 indexed citations

15.

Gelb, Arnold B., Ronald F. Dorfman, & Roger A. Warnke. (1993). Coexistence of Nodular Lymphocyte Predominance Hodgkinʼs Disease and Hodgkinʼs Disease of the Usual Type. The American Journal of Surgical Pathology. 17(4). 364–374. 9 indexed citations

16.

Gelb, Arnold B., et al.. (1993). Stage I Renal Cell Carcinoma. The American Journal of Surgical Pathology. 17(3). 275–286. 69 indexed citations

17.

Gelb, Arnold B., Kenneth H. Fye, Jay A. Tischfield, et al.. (1992). Renal insufficiency secondary to 2,8-dihydroxyadenine urolithiasis. Human Pathology. 23(9). 1081–1085. 6 indexed citations

18.

Carmelli, Dorit, Jerry Halpern, Gary E. Swan, et al.. (1991). 27-Year mortality in the Western collaborative group study: construction of risk groups by recursive partitioning. Journal of Clinical Epidemiology. 44(12). 1341–1351. 40 indexed citations

19.

Cibas, Edmund S., L. Jeffrey Medeiros, David S. Weinberg, Arnold B. Gelb, & Lawrence M. Weiss. (1990). Cellular DNA Profiles of Benign and Malignant Adrenocortical Tumors. The American Journal of Surgical Pathology. 14(10). 948–955. 44 indexed citations

20.

Medeiros, L. Jeffrey, Arnold B. Gelb, & Lawrence M. Weiss. (1988). Renal cell carcinoma.Prognostic significance of morphologic parameters in 121 cases. Cancer. 61(8). 1639–1651. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact